WELCOME to epgonline.org

Welcome to epgonline.org, a free online source of credible and independent scientific content intended for healthcare professionals in the United States that brings all the medical information you need into one place, providing education and guidance to help with the diagnosis and treatment of your patients.

This website provides:

  • Drug information, categorised using the ATC Classification System, providing indication, dosage, administration and precautions.
  • Specialty and disease information, categorising specialties and diseases using the ICD-10 classification, with further insight found in the Disease Focus area.
  • The Horizons series of articles, written by our team of specialists, that ask what the future of healthcare holds, evaluating emerging trends to provide expert insight.
  • The latest news to keep you up-to-date with current advancements in drug development, advocacy and awareness, industry mergers and acquisitions, clinical trial progression and congress information.
  • Recent opinion articles shared with us by healthcare professionals to express their views and experiences.
  • A wide variety of accredited internal and external CME modules and courses, designed to educate on the latest care strategies for specific conditions.
  • The latest studies, trials and guidelines from global publications provide a comprehensive collection of current and past developments in medicine, helping you to provide best practice.
  • Medical applications that deliver creative solutions to aid in the diagnosis and treatment of your patients.
  • Specialist educational microsites, or Learning Zones, each devoted to self-directed medical education surrounding a specific disease, condition or procedure.

Registration is quick and simple, giving you unlimited access to all content and features, allowing you to save pages, comment on your favourite articles and access the personalised dashboard.

Latest News

Added 7 hours ago Drug news

FDA approves prescription digital therapeutic, reSET-O for patients with opioid use disorder. Sandoz.

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, announced that the FDA...

Added 7 hours ago Drug news

Phase III study of Liletta for contraception published in American Journal of Obstetrics & Gynecology.- Medicines360/Allergan.

Medicines360/Allergan announced newly published data finding that Liletta (levonorgestrel releasing intrauterine system) is highly efficacious in preventing pregnancy over five...

Added 7 hours ago Drug news

New data demonstrates IV meloxicam’s effect on platelet function.- Recro Pharma

Recro Pharma, Inc. announced a poster presentation highlighting intravenous (IV) meloxicam’s effect on platelet function at the 72nd PostGraduate Assembly...

LOOKING TO THE HORIZON - BREAKTHROUGH DRUGS AND TREATMENTS

Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Posted 1 year ago

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Penny Staton

Improving non-alcoholic steatohepatitis care – is the finishing line in sight?

Posted 1 year ago

An intense race is going on right now in non-alcoholic steatohepatitis (NASH) research. A number of significant players within the pharmaceutical and biotechnology sectors are competing to develop the first major therapeutic advance in treatment for this neglected condition. But should we consider it more of a relay race? Could improved diagnosis, disease assessment and even combination therapy be the key to victory over this increasingly prevalent disease?

Marshall Pearce

How close are we to a disease-modifying treatment for Alzheimer’s?

Posted 1 year ago

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.